Abstract:Exquisite binding specificity is essential for many protein functions but is difficult to engineer. Many biotechnological or biomedical applications require the discrimination of very similar ligands, which poses the challenge of designing protein sequences with highly specific binding profiles. Experimental methods for generating specific binders rely on in vitro selection, which is limited in terms of library size and control over specificity profiles. Additional control was recently demonstrated through high-throughput sequencing and downstream computational analysis. Here we follow such an approach to demonstrate the design of specific antibodies beyond those probed experimentally. We do so in a context where very similar epitopes need to be discriminated, and where these epitopes cannot be experimentally dissociated from other epitopes present in the selection. Our approach involves the identification of different binding modes, each associated with a particular ligand against which the antibodies are either selected or not. Using data from phage display experiments, we show that the model successfully disentangles these modes, even when they are associated with chemically very similar ligands. Additionally, we demonstrate and validate experimentally the computational design of antibodies with customized specificity profiles, either with specific high affinity for a particular target ligand, or with cross-specificity for multiple target ligands. Overall, our results showcase the potential of leveraging a biophysical model learned from selections against multiple ligands to design proteins with tailored specificity, with applications to protein engineering extending beyond the design of antibodies. A great challenge in protein science is to relate sequences to physical properties, both to predict physical properties from sequences, and to design sequences with desired phenotypes. A promising solution lies in integrating large-scale selection experiments, high-throughput sequencing, and machine learning techniques. However, existing models often focus solely on the property under selection ("fitness"), lacking interpretability. This limits our fundamental understanding of proteins and our ability to engineer them for desired properties, especially those not directly selectable in experiments. Previous studies have shown that incorporating biophysical constraints into models can offer quantitative insights, particularly in transcription factors Here, we demonstrate that when coupled with extensive experiments, such modeling can not only predict physical features but also design new proteins with specific properties. Our demonstration involves a problem of primary biotechnological and biomedical interest: the design of antibodies with defined specificity profiles. We focus on one of the most challenging tasks in the field, designing antibodies capable of discriminating between structurally and chemically similar ligands. This approach has applications for creating antibodies with both specific and cross-specific binding properties and for mitigating experimental artifacts and biases in selection experiments. The combination of biophysics-informed modeling and extensive selection experiments holds broad applicability beyond antibodies, offering a powerful toolset for designing proteins with desired physical properties.

Engineering high affinity antigen-binders: Beyond conventional antibodies

Monoclonal antibodies: technologies for early discovery and engineering

Advances in Antibody-Based Therapeutics: From Design to Clinical Applications

Biological Applications of Synthetic Binders Isolated from a Conceptually New Adhiron Library

Antibody Conjugates-Recent Advances and Future Innovations

A Current Perspective on Applications of Macrocyclic-Peptide-based High-Affinity Ligands.

New protein engineering approaches to multivalent and bispecific antibody fragments

Binding proteins from alternative scaffolds

Advancing Antibody Engineering through Synthetic Evolution and Machine Learning

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Genetic Engineering Antibody Fragments -A Novel Tune for the Antibody Family

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Affimers As Anti-Idiotypic Affinity Reagents for Pharmacokinetic Analysis of Biotherapeutics.

Affimer Proteins Are Versatile and Renewable Affinity Reagents

Engineering therapeutic monoclonal antibodies

Emerging affinity ligands and support materials for the enrichment of monoclonal antibodies

Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies

Learned features of antibody-antigen binding affinity

Protein engineering approaches for antibody fragments: directed evolution and rational design approaches

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries

Inference and design of antibody specificity: From experiments to models and back